Statements (52)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:immunotherapy
|
gptkbp:activities |
effective against influenza A and B viruses
|
gptkbp:administered_by |
intravenous injection
|
gptkbp:approves |
gptkb:2014
gptkb:FDA |
gptkbp:availability |
available by prescription only
|
gptkbp:brand |
gptkb:Rapivab
|
gptkbp:casnumber |
209216-23-9
|
gptkbp:chemical_formula |
C16 H20 N2 O4
|
gptkbp:clinical_trial |
completed
Phase III trials completed |
gptkbp:clinical_use |
treatment of influenza in adults and children
|
gptkbp:contraindication |
hypersensitivity to peramivir
|
gptkbp:developed_by |
gptkb:Bio_Cryst_Pharmaceuticals
|
gptkbp:drug_interactions |
minimal drug interactions
|
gptkbp:duration |
single dose treatment
|
gptkbp:effective_date |
December 2014
|
gptkbp:excretion |
primarily through urine
|
gptkbp:formulation |
lyophilized powder for reconstitution
|
https://www.w3.org/2000/01/rdf-schema#label |
Peramivir
|
gptkbp:indication |
acute uncomplicated influenza
|
gptkbp:is_effective_against |
demonstrated efficacy in clinical trials
|
gptkbp:marketed_as |
gptkb:Rapivab
|
gptkbp:mechanism_of_action |
neuraminidase inhibitor
|
gptkbp:metabolism |
not extensively metabolized
|
gptkbp:notable_work |
shown to reduce duration of symptoms
|
gptkbp:packaging |
single-use vial
|
gptkbp:patient_education |
patients advised to report side effects
|
gptkbp:patient_population |
adults and pediatric patients
|
gptkbp:pharmacokinetics |
inhibits viral replication
elimination half-life of approximately 20 hours |
gptkbp:price |
varies by pharmacy
|
gptkbp:production_status |
approved for use in the United States
|
gptkbp:provides_guidance_on |
recommended for high-risk patients
CDC recommends use in certain cases |
gptkbp:research_institutes |
studied in multiple clinical research centers
|
gptkbp:research_status |
ongoing studies for efficacy in other viral infections
|
gptkbp:route_of_administration |
IV
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:safety_measures |
monitored post-marketing
|
gptkbp:service_frequency |
once daily for 1 day
|
gptkbp:side_effect |
headache
nausea diarrhea allergic reactions possible elevated liver enzymes |
gptkbp:storage |
store at room temperature
|
gptkbp:supply_chain |
manufactured under strict regulations
|
gptkbp:target_audience |
patients with influenza
|
gptkbp:used_for |
treatment of influenza
|
gptkbp:bfsParent |
gptkb:Daiichi_Sankyo
|
gptkbp:bfsLayer |
5
|